EM2P2

EM2P2 is a pre-clinical stage biotechnology company specializing in regenerative medicine through the use of extracellular matrix-derived peptides. The company's core technology is based on a synthetic 12-amino acid peptide that mimics the pro-angiogenic properties of elastin to stimulate blood vessel growth and tissue repair. EM2P2 is currently developing this platform for the treatment of ischemic diseases, including peripheral artery disease and myocardial infarction, as well as chronic wound healing. By utilizing small synthetic peptides, the company aims to offer a more stable and cost-effective alternative to traditional protein-based regenerative therapies.